Catherine R Sheils1, William S Fischer1, Rachel A Hollar1, Lisa M Blanchard1, Steven E Feldon2. 1. University of Rochester School of Medicine & Dentistry, Rochester, New York, USA; Department of Ophthalmology, David & Ilene Flaum Eye Institute, Rochester, New York, USA. 2. University of Rochester School of Medicine & Dentistry, Rochester, New York, USA; Department of Ophthalmology, David & Ilene Flaum Eye Institute, Rochester, New York, USA. Electronic address: Steven_Feldon@URMC.rochester.edu.
Abstract
PURPOSE: To compare measurements of papilledema using fundus photography, optical coherence tomography (OCT), and Frisén score in patients with idiopathic intracranial hypertension (IIH). DESIGN: Retrospective, noncomparative analysis of randomized controlled trial data. METHODS: The Idiopathic Intracranial Hypertension Treatment Trial (IIHTT) evaluated weight management and treatment with acetazolamide compared with placebo in patients with IIH and mild visual loss. Among the 126 subjects in the IIHTT OCT substudy, fundus photographs and OCT scans of the optic disc were taken at baseline and at 6 and 12 months after enrollment. Trained readers scored each eye using a modified Frisén scale and measured the area of disc elevation. OCT scans assessed optic nerve head (ONH) volume. Correlations between volume and area were computed for both study and nonstudy eyes. RESULTS:Disc area and ONH volume were positively correlated at baseline (R2 = 0.77 in study eyes, P < .001). Correlations between area and volume were similar in the treatment groups at baseline, but were weaker in the acetazolamide group compared with the placebo group at 6 months (R2 = 0.25 vs R2 = 0.76 in study eyes) and 12 months (R2 = 0.19 vs R2 = 0.65 in study eyes). At 6 and 12 months after enrollment, there was no consistent relationship between Frisén score, disc area, and ONH volumes in the acetazolamide group. CONCLUSION: Frisén score fails to reflect the photographic area and OCT volume of papilledema after treatment with acetazolamide. Clinicians should use caution when using the Frisén scale to monitor the effect of treatment on papilledema over time.
RCT Entities:
PURPOSE: To compare measurements of papilledema using fundus photography, optical coherence tomography (OCT), and Frisén score in patients with idiopathic intracranial hypertension (IIH). DESIGN: Retrospective, noncomparative analysis of randomized controlled trial data. METHODS: The Idiopathic Intracranial Hypertension Treatment Trial (IIHTT) evaluated weight management and treatment with acetazolamide compared with placebo in patients with IIH and mild visual loss. Among the 126 subjects in the IIHTT OCT substudy, fundus photographs and OCT scans of the optic disc were taken at baseline and at 6 and 12 months after enrollment. Trained readers scored each eye using a modified Frisén scale and measured the area of disc elevation. OCT scans assessed optic nerve head (ONH) volume. Correlations between volume and area were computed for both study and nonstudy eyes. RESULTS: Disc area and ONH volume were positively correlated at baseline (R2 = 0.77 in study eyes, P < .001). Correlations between area and volume were similar in the treatment groups at baseline, but were weaker in the acetazolamide group compared with the placebo group at 6 months (R2 = 0.25 vs R2 = 0.76 in study eyes) and 12 months (R2 = 0.19 vs R2 = 0.65 in study eyes). At 6 and 12 months after enrollment, there was no consistent relationship between Frisén score, disc area, and ONH volumes in the acetazolamide group. CONCLUSION: Frisén score fails to reflect the photographic area and OCT volume of papilledema after treatment with acetazolamide. Clinicians should use caution when using the Frisén scale to monitor the effect of treatment on papilledema over time.
Authors: Li Tang; Randy H Kardon; Jui-Kai Wang; Mona K Garvin; Kyungmoo Lee; Michael D Abràmoff Journal: Invest Ophthalmol Vis Sci Date: 2012-07-03 Impact factor: 4.799
Authors: Michael Wall; Michael P McDermott; Karl D Kieburtz; James J Corbett; Steven E Feldon; Deborah I Friedman; David M Katz; John L Keltner; Eleanor B Schron; Mark J Kupersmith Journal: JAMA Date: 2014 Apr 23-30 Impact factor: 56.272
Authors: Peggy Auinger; Mary Durbin; Steven Feldon; Mona Garvin; Randy Kardon; John Keltner; Mark Kupersmith; Patrick Sibony; Kim Plumb; Jui-Kai Wang; John S Werner Journal: Invest Ophthalmol Vis Sci Date: 2014-11-04 Impact factor: 4.799
Authors: Michael Wall; Mark J Kupersmith; Matthew J Thurtell; Heather E Moss; Elizabeth Ann Moss; Peggy Auinger Journal: Am J Ophthalmol Date: 2017-01-17 Impact factor: 5.258
Authors: Peggy Auinger; Mary Durbin; Steven Feldon; Mona Garvin; Randy Kardon; John Keltner; Mark J Kupersmith; Patrick Sibony; Kim Plumb; Jui-Kai Wang; John S Werner Journal: Invest Ophthalmol Vis Sci Date: 2014-11-04 Impact factor: 4.799
Authors: Alexandra J Sinclair; Michael A Burdon; Peter G Nightingale; Timothy D Matthews; Andrew Jacks; Mark Lawden; Arul Sivaguru; Brent J Gaskin; Saaeha Rauz; Carl E Clarke; Alexandra K Ball Journal: J Neurol Date: 2012-01-12 Impact factor: 4.849
Authors: Philipp Hendrix; Christopher J Whiting; Christoph J Griessenauer; Christian Bohan; Clemens M Schirmer; Oded Goren Journal: Neurosurg Rev Date: 2022-01-24 Impact factor: 3.042